insulin secretagogues - DPP-4 inhibitors

     

Select            
Trial Studied trt Control trt patientstagsROB Trial resultAdverse events leading to treatment discontinuationcardiovascular events

diabetes type 2

alogliptin
Seino, 2011      NCTalogliptin -
Seino, 2011     alogliptin -
Bosi , 2011      NCTalogliptin -
Kaku, 2011     alogliptin -
Rosenstock, 2010      NCTalogliptin -
Rosenstock, 2009      NCTalogliptin -
Pratley, 2009      NCTalogliptin -
Pratley, 2009      NCTalogliptin -
DeFronzo , 2008      NCTalogliptin -
EXAMINE, 2011        NCTalogliptinplacebonegative-4%
Nauck, 2009      NCTalogliptinplacebo (add on MET)Low risk of bias negative
linagliptin
Forst, 2010      NCTlinagliptinLow risk of bias -
CAROLINA, 2012      NCTlinagliptinglimepirideLow risk of bias suggesting-54%
Gallwitz, 2012      NCTlinagliptinglimepiride (add on MET)Low risk of bias -
Owens      NCTlinagliptinMetformin + sulfonylurea -
Del Prato      NCTlinagliptinplaceboLow risk of bias -
Taskinen      NCTlinagliptinplacebo (add on MET) -
Gomis, 2011      NCTlinagliptinplacebo (add on pioglitazone) -
Lewin, 2010    NCTlinagliptinplacebo (add on SU)Low risk of bias -
saxagliptin
Kawamori, 2012        NCTsaxagliptin -
Forst, 2011   Saxagliptin -
Fonseca, 2012      NCTsaxagliptin -
Nowicki, 2011      NCTsaxagliptin -
Yang, 2011      NCTsaxagliptin -
Nowicki, 2011      NCTsaxagliptin -
Göke, 2010     saxagliptin -
Scheen , 2010     saxagliptin -
Stenlöf , 2010     Saxagliptin -
CV181-040      NCTsaxagliptin + glyburideglyburide uptitration -
CV181-085    NCTsaxagliptin plus metformin XR 1500mgmetformin up to 2000mg -
SAVOR-TIMI 53, 2013        NCTsaxagliptinplacebonegative 0%
saxgliptin, renal study   saxagliptinplacebo (add on current treatment) -
CV181-057    NCTsaxagliptinplacebo (add on insulin) -
DeFronzo, 2009      NCTsaxagliptinplacebo (add on MET)negative
Jadzinsky, 2009      NCTsaxagliptinplacebo (add on MET) -
CV181-066    NCTsaxagliptinplacebo (add on MET) -
CV181-080    NCTsaxagliptinplacebo (add on MET) -
Hollander      NCTsaxagliptinplacebo (add on TZD) -
Rosenstock, 2008    NCTsaxagliptinplacebo (monotherapy) -
CV181-011      NCTsaxagliptinplacebo (monotherapy) -
CV181-038    NCTsaxagliptinplacebo (monotherapy) -
CV181-041    NCTsaxagliptinplacebo (monotherapy) -
saxagliptin vs sitagliptin   saxagliptinsitagliptin (add on MET) -
saxagliptin   saxagliptinglipizideLow risk of bias -
sitagliptin
Stafford , 2011      NCTsitagliptin -
Reasner, 2011      NCTsitagliptincontrol (add on MET) -
Arechavaleta, 2011      NCTsitagliptinglimepiride (add on MET)Low risk of bias -
Aschner, 2010      NCTsitagliptin monotherapymetforminLow risk of bias -
Derosa , 2010     sitagliptin+piometformin+pio -
Goldstein, 2007      NCTsitagliptinplacebonegative-26%
Hanefeld, 2007     sitagliptinplacebonegative1%
Scott* (sit vs pbo), 2007     sitagliptin 50mg bid monotherapyplacebonegative207%
Aschner, 2006      NCTsitagliptin monotherapyplacebonegative-4%
Nonaka, 2008      NCTsitagliptin monotherapyplaceboLow risk of bias negative-100%
Raz, 2006     sitagliptin monotherapyplacebonegative-100%
Barzilai, 2011      NCTsitagliptin monotherapyplaceboLow risk of bias -
Mohan , 2009     sitagliptin monotherapyplaceboLow risk of bias -
Chan, 2008     sitagliptin monotherapyplaceboLow risk of bias -
Vilsbøll, 2010      NCTsitagliptinplacebo (add on insulin+/-MET)Low risk of bias -
Charbonnel, 2006      NCTsitagliptinplacebo (add on MET)negative34%
Nauck, 2007          NCTsitagliptinplacebo (add on MET)negative-24%
Scott** (sit vs pbo on top met), 2007     sitagliptinplacebo (add on MET)negative287%
raz, 2008      NCTsitagliptinplacebo (add on MET) -
Rosenstock , 2006      NCTsitagliptinplacebo (add on PIO)Low risk of bias -
Rosenstock (sit on top pio vs pbo), 2006      NCTsitagliptinplacebo (on top PIO)suggesting459%
Hermansen, 2007     sitagliptinplacebo (on-top glimepiride+/- metformine)negative174%
Rigby , 2010     sitagliptinrosiglitazone (add on MET) -
Al Sifri, 2011     sitagliptinSulphonylurea (on top MET) -
Iwamoto , 2010     sitagliptin monotherapyvogliboseLow risk of bias -
Scott* (sit vs glipi), 2007     sitagliptin 50mg bid monotherapyglipizideLow risk of bias -
Goldstein (sit vs met), 2007     sitagliptinmetformin -
Goldstein (sit+met vs met), 2007     sitagliptinmetformin -
Pérez-Monteverde, 2011      NCTsitagliptinpioglitazoneLow risk of bias -
vildagliptin
NCT00101673      NCTvildagliptin -
Pan, 2008      NCTvildagliptin monotherapyacarboseLow risk of bias -
Foley, 2009      NCTvildagliptin monotherapygliclazideLow risk of bias -
Filozof, 2009      NCTvildagliptingliclazide (add on MET)Low risk of bias -
Matthews , 2010     vildagliptinglimepiride (add on MET)Low risk of bias -
CLAF237A 23104    NCTvildagliptin + METMET -
Schweizer, 2009      NCTvildagliptinmetformin -
Mimori, 2006   vildagliptinplacebo -
Scherbaum [2], 2008          NCTvildagliptinplaceboLow risk of bias negative124%
Rosenstock, 2008      NCTvildagliptinplaceboLow risk of bias -
NCT00351832    NCTvildagliptinplacebo -
Dejager [1], 2007      NCTvildagliptin monotherapyplaceboLow risk of bias negative1%
Pi-Sunyer, 2007      NCTvildagliptin monotherapyplaceboLow risk of bias suggesting338%
Pratley, 2006     vildagliptin monotherapyplaceboLow risk of bias negative+Infini%
Ristic, 2005     vildagliptin monotherapyplacebonegative-40%
Foley, 2011      NCTvildagliptin monotherapyplacebo -
Kikuchi, 2009     vildagliptin monotherapyplacebo -
Ahren, 2009    NCTvildagliptin monotherapyplacebo -
Lukashevich , 2011     vildagliptinplacebo (add on current therapy) -
Kikuchi, 2010      NCTvildagliptinplacebo (add on glimepiride)Low risk of bias -
Fonseca, 2007      NCTvildagliptinplacebo (add on insulin)Low risk of bias suggesting850%
Fonseca , 2008     vildagliptinplacebo (add on insulin) -
Ahren, 2004     vildagliptinplacebo (add on MET)Low risk of bias negative
Bosi, 2007      NCTvildagliptinplacebo (add on MET)Low risk of bias negative73%
Goodman, 2009     vildagliptinplacebo (add on MET)Low risk of bias negative
Bosi, 2009      NCTvildagliptinplacebo (add on MET) -
NCT00728351    NCTvildagliptinplacebo (add on MET) -
NCT00822211    NCTvildagliptinplacebo (add on MET) -
NCT00494884 (Wollmer)    NCTvildagliptinplacebo (add on MET) -
NCT00396071    NCTvildagliptinplacebo (add on MET) -
Garber, 2008      NCTvildagliptinplacebo (add on SU)Low risk of bias -
Garber, 2007      NCTvildagliptinplacebo (on top pioglitazone)negative25%
Rosenstock, 2009    NCTvildagliptinrosiglitazoneLow risk of bias -
Ferrannini, 2009      NCTvildagliptinSulfonylurea (add on to MET)Low risk of bias suggesting
GALIANT (Blonde), 2009      NCTvildagliptinTZD (add on MET) -
NCT00368134    NCTvildagliptinvoglibose -
Iwamoto, 2010     vildagliptinvogliboseLow risk of bias -
Schweizer, 2007        NCTvildagliptinmetforminnegative-42%
Goke, 2008     vildagliptinmetformin -
Rosenstock** (vilda vs pio), 2007      NCTvildagliptin monotherapypioglitazoneLow risk of bias -
Bolli, 2008        NCTvildagliptinpioglitazone (add on MET)Low risk of bias negative-5%
Rosenstock** (vilda + pio vs pio), 2007      NCTvildagliptinplacebo (add on TZD)Low risk of bias negative-53%
Rosenstock* (vilda vs rosi), 2007        NCTvildagliptinrosiglitazoneLow risk of bias -